Key result
Atorvastatin, olmesartan, resveratrol, and their combination significantly reduced TGF-β1-induced α-smooth muscle actin expression in valvular interstitial cells compared to control (p<0.001).
Why the study?
Valvular interstitial cell differentiation into myofibroblasts drives pathological valve remodeling in rheumatic valvular disease, but the effects of atorvastatin, olmesartan, and resveratrol on this fibrosis were unknown.
Does atorvastatin, olmesartan, resveratrol, or their combination reduce TGF-β1-induced myofibroblast differentiation in rabbit valvular interstitial cells?
Does atorvastatin, olmesartan, resveratrol, or their combination reduce TGF-β1-induced myofibroblast differentiation in rabbit valvular interstitial cells?
Atorvastatin, olmesartan, resveratrol, and their combination significantly inhibit TGF-β1-induced pathological myofibroblast differentiation of valvular interstitial cells in an in vitro rabbit model.
Answers are grounded in this paper and cite their sources.
Supports exploration of repurposed agents for valvular fibrosis; leaves open translation from this in vitro rabbit model.
Introduction. Recent studies revealed that differentiation of valvular interstitial cell into myofibroblasts played an important role in pathological valve remodeling in rheumatic valvular disease. Objective. To investigate effects of atorvastatin, olmesartan, and resveratrol on Transforming Growth Factor β1-induced fibrosis. Methods. Valvular interstitial cell was isolated from 12-weeks male New Zealand rabbit (Oryctolagus cuniculus). Culture cells was divided into 4 groups, control group, group I (0.5 mg/mL Atorvastatin), group II (100 nmol/L Olmesartan), group III (50 μM/L Resveratrol) and group IV (combinations). All group were exposed to 100 nM Transforming Growth Factor β1 for 24 hours. Results. Immunochemical staining demonstrated that cells were completely differentiated into myofibroblasts with mean expression of α-smooth muscle actin 24522.64±4566.994. Atorvastatin, olmesartan, resveratrol, and its combination significantly reduced α-smooth muscle actin expression (6823±1735.3, 6942.7±2455.9, 14176.2±3343.3, 5051.8±1612.2 respectively (p<0.001). Conclusion. Our data showed atorvastatin, olmesartan, resveratrol, and its combination significantly reduce Transforming Growth Factor β1-induced valvular fibrosis.
No takes yet. Share an insight, caveat, or question.
Suwanto et al. (2022) studied Valvular fibrosis. Atorvastatin, Olmesartan, Resveratrol, and their combination vs. TGF-β1 exposed control group was evaluated on α-smooth muscle actin (α-SMA) expression (p=<0.001). Atorvastatin, olmesartan, resveratrol, and their combination significantly reduced TGF-β1-induced α-smooth muscle actin expression in valvular interstitial cells compared to control (p<0.001).
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: